Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

AI Stocks Roar to Record Highs Amid Bold Deals and China Backlash (Aug 12–13, 2025 Roundup)

AI Stocks Roar to Record Highs Amid Bold Deals and China Backlash (Aug 12–13, 2025 Roundup)

On August 12, 2025, Nasdaq Composite and S&P 500 closed at record highs as AI stocks drove gains and cooling inflation boosted expectations for a Fed rate cut. Nvidia (NVDA) surged to an intraday high of about $184.50 on August
Space Race Heats Up: Epic Launches, Lunar Showdowns & Breakthrough Tech (Aug 12–13, 2025 Roundup)

Space Race Heats Up: Epic Launches, Lunar Showdowns & Breakthrough Tech (Aug 12–13, 2025 Roundup)

Rocket Launch Triumphs: New Heavy-Lifters and Constellation Boosts Lunar Missions & Spaceflight Milestones: Moon Race Intensifies Next-Gen Satellite Tech & Services: Innovation in Orbit Space Policy & International Developments: Safety, Funding, and Collaboration Sources: Spaceflight Now spaceflightnow.com spaceflightnow.com spaceflightnow.com; Space.com
AI’s Wild 48 Hours: Bold $34B Bids, Breakthrough Bots & High-Stakes Showdowns (Aug 12–13, 2025)

AI’s Wild 48 Hours: Bold $34B Bids, Breakthrough Bots & High-Stakes Showdowns (Aug 12–13, 2025)

MolmoAct 7B, unveiled by Seattle’s Allen Institute for AI (Ai2), is a 7‑billion‑parameter open‑source model that lets robots plan 3D trajectories before execution and achieved 72%+ success on simulated benchmarks. Beijing‑based Zhipu AI released GLM‑4.5V, a 106B‑parameter open‑source visual reasoning
Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

IO Biotech’s Phase 3 melanoma vaccine Cylembia added to Merck’s Keytruda narrowly missed statistical significance, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. Fosun Pharma’s deal with Expedition Therapeutics grants rights outside Greater China to
1 182 183 184 185 186 219
Go toTop